The UK and US have reached a key trade agreement that will preserve zero levies on British medicine products being sold in the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase funding on pharmaceuticals through the public health system. This move secures that tariffs on these key goods will remain at nothing for a period of the next three years.
This development comes after earlier statements to hike duties on patented drug imports, with figures mentioned reaching 100%.
"This deal between the United Kingdom strengthens the worldwide climate for new treatments and brings much-needed balance to U.S.–U.K. drug exports," an announcement said.
Commercial Significance
Medicines constitute one of the UK's largest goods shipped to the America, which is easily the largest buyer for large companies like GSK and AstraZeneca.
Trade data indicate that in the year prior to last September, the UK shipped drugs totaling £11.1bn to the US. This amount accounted for 17.4% of British export trade in that timeframe.
"This deal safeguards jobs, stimulates investment and paves the way for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key UK Commitments
The agreement includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to double overall NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. Previously, rebates were more than 20%.
Industry Background
The deal takes place against a ongoing dispute between the pharmaceutical industry and the ministers over drug pricing and approval rates.
These tensions were heightened by claims that American patients were charged significantly more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or cancelled, while substantial investments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the past decade.
